Cargando…

SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response

Detalles Bibliográficos
Autores principales:	Verhoeven, Frank, Lepiller, Quentin, Hecquet, Sophie, Prati, Clément, Wendling, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Société française de rhumatologie. Published by Elsevier Masson SAS. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411658/ https://www.ncbi.nlm.nih.gov/pubmed/34481943 http://dx.doi.org/10.1016/j.jbspin.2021.105258

Ejemplares similares

Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281
por: Verhoeven, Frank, et al.
Publicado: (2022)

Answer to De Marchi et al. Joint Bone Spine 2022;89:105408
por: Verhoeven, Frank, et al.
Publicado: (2022)

Can SARS-CoV-2 trigger reactive arthritis?
por: Wendling, Daniel, et al.
Publicado: (2021)

Interest of Follow-Up Radiological Imaging in Patients with Pyogenic Vertebral Osteomyelitis
por: Hecquet, Sophie, et al.
Publicado: (2021)

Le SARS-CoV-2 peut-il induire une arthrite réactionnelle ?()
por: Wendling, Daniel, et al.
Publicado: (2021)

Frequency and anatomic distribution of magnetic resonance imaging lesions in the sacroiliac joints of spondyloarthritis and non-spondyloarthritis patients
por: Hecquet, Sophie, et al.
Publicado: (2022)

SARS CoV-2 vaccine AND rituximab. Comment on: “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response” by Verhoeven Joint Bone Spine. 2021;88:105258
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Amyloidoma, an Unusual Cause of Fracture
por: Verhoeven, Frank, et al.
Publicado: (2014)

ChatGPT: when artificial intelligence replaces the rheumatologist in medical writing
por: Verhoeven, Frank, et al.
Publicado: (2023)

SARS-CoV-2 Vaccination Effectiveness in Rituximab-Treated Patients Affected by Pemphigus Vulgaris
por: Fenizia, Claudio, et al.
Publicado: (2023)

Comment on: “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response” by Verhoeven et al. Joint Bone Spine 2021;88:105258
por: De Marchi, Ginevra, et al.
Publicado: (2022)

Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab
por: Benucci, Maurizio, et al.
Publicado: (2021)

Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab”
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Polymyalgia Rheumatica Revealing a Lymphoma: A Two-Case Report
por: Verhoeven, Frank, et al.
Publicado: (2016)

Glucocorticoids and endothelial function in inflammatory diseases: focus on rheumatoid arthritis
por: Verhoeven, Frank, et al.
Publicado: (2016)

Dengue After COVID-19 Vaccination: Possible and Might be Missed
por: Kebayoon, Amnuay, et al.
Publicado: (2021)

SARS-CoV-2: eye protection might be the missing key
por: Coroneo, Minas Theodore, et al.
Publicado: (2021)

Increased gut permeability and intestinal inflammation precede arthritis onset in the adjuvant-induced model of arthritis
por: Hecquet, Sophie, et al.
Publicado: (2023)

T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients
por: Heitz, Jade, et al.
Publicado: (2022)

Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases
por: Oliosi, E., et al.
Publicado: (2023)

Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters()
por: Magliulo, Daniel, et al.
Publicado: (2022)

Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis
por: Smith, Jessica B., et al.
Publicado: (2022)

Subchondral bone attenuation coefficient utility of the sacroiliac margins to differentiate spondyloarthritis and osteitis condensans ilii
por: Terrier, Alexandre, et al.
Publicado: (2022)

Comparison of sacroiliac CT findings in patients with and without ankylosing spondylitis aged over 50 years
por: Fakih, Olivier, et al.
Publicado: (2023)

Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study
por: Fakih, Olivier, et al.
Publicado: (2023)

Low rates of humoral response to BNT162b2 SARS-CoV-2 vaccination in patients with immune-mediated kidney diseases treated with rituximab
por: Demoulin, Nathalie, et al.
Publicado: (2021)

Leukocytoclastic Vasculitis and SARS-COV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Esophagitis and SARS-CoV-2 vaccine
por: Sriwijitalai, Won, et al.
Publicado: (2023)

Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients
por: Woo, Marcel S., et al.
Publicado: (2020)

SARS-CoV-2 related myocardial injury might explain the predisposition to preeclampsia with maternal SARS-CoV-2 infection
por: Giorgione, Veronica, et al.
Publicado: (2022)

Minimal change disease relapse following SARS-CoV-2 mRNA vaccine
por: Kervella, Delphine, et al.
Publicado: (2021)

SARS CoV-2 viral load might not be the right predictor of COVID-19 mortality
por: Kelleni, Mina T.
Publicado: (2021)

Might hydrogen peroxide reduce the hospitalization rate and complications of SARS-CoV-2 infection?
por: Caruso, Arturo A., et al.
Publicado: (2020)

Public health might be endangered by possible prolonged discharge of SARS-CoV-2 in stool
por: He, Yu, et al.
Publicado: (2020)

Late and booster anti‐SARS‐CoV‐2 humoral responses in nonresponder vaccinated patients with rheumatic diseases receiving mycophenolate or rituximab: comment on the article by XXX et al
por: Bakasis, Athanasios‐Dimitrios, et al.
Publicado: (2022)

SARS-CoV-2 and the myths about vaccination()
por: Travezaño-Cabrera, Aaron, et al.
Publicado: (2021)

Immunophenotyping of SARS-CoV-2 and vaccine design
por: Cimolai, Nevio
Publicado: (2022)

Esophagitis and SARS-CoV-2 vaccine: Correspondence
por: Sriwijitalai, Won, et al.
Publicado: (2023)

Comment on the effectiveness of four SARS-COV-2 vaccines
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Persistence of SARS-CoV-2 antibodies in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ove7lomkp7q3t2sd927j1p29k6